Read our COVID-19 research and news.

Webinar Technology

New horizons in therapeutic antibody discovery: Challenges and opportunities for improvement

This webinar is brought to you by the Science/AAAS Custom Publishing Office

New horizons in therapeutic antibody discovery: Challenges and opportunities for improvement

17 June 2020

12:00 p.m. ET

Register to watch recording


Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anticancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy, and bispecific T-cell engagers. While these approaches use different tactics to attack tumors, they often employ monoclonal antibodies to target specific antigens. In this highly competitive field, it is crucial to identify candidate antibodies with superior target reactivity. The first step in this process involves screening antibody libraries to identify binders. This can be achieved by using either display technologies or animal immunization. Once antibodies have been identified and slated for production, they must be further characterized and tested for performance-related characteristics before moving into preclinical testing.

During the webinar, the speakers will:

  • Provide an overview of the therapeutic antibody discovery landscape
  • Discuss the successes and limitations of current antibody discovery technologies
  • Offer case studies of antibody screening and characterization
  • Answer viewer questions during the live broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Paul J. Carter, Ph.D.

Genentech, Inc.
South San Francisco, CA

Dr. Carter received a B.A. in Natural Sciences from Cambridge University and his Ph.D. in molecular biology under Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge. He then completed a postdoctoral fellowship with James Wells at Genentech, now a member of the Roche Group. Dr. Carter has over thirty years of experience in biotechnology focusing on the discovery of antibody therapeutics. He played a key role in the creation of antibody humanization methods at Genentech, utilized over many years for nine approved antibody products used to treat millions of patients worldwide. He and his collaborators invented “knobs-into-holes” technology widely used in generating bispecific antibodies. He is currently a Genentech Fellow in the Department of Antibody Engineering at Genentech.

Daniel S. Chen, M.D., Ph.D.

IGM Biosciences
Mountain View, CA

Dr. Chen received a B.S. in biology from the Massachusetts Institute of Technology (1990), then received a Ph.D. in microbiology and immunology (1996) and an M.D. (1998) from the University of Southern California. He completed an internal medicine residency and medical oncology fellowship at Stanford University (2003). He went on to complete a postdoctoral fellowship at Stanford with Mark Davis in immunology, where he was a Howard Hughes Medical Institute Associate. He also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003 to 2006. During that time, he studied human anticancer immune responses, pre- and postcancer vaccination, and cytokine administration to determine why antitumor immune responses were not more clinically effective. While working at Genentech from 2006 to 2018, Dr. Chen focused on the clinical development of antiangiogenic and immune modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development. This included leading clinical development for atezolizumab, a PD-L1 inhibitor, from basic research into the investigational new drug (IND) process, through Phase I, II, and III trials, to filing and approvals in multiple indications worldwide. At IGM Biosciences, he focuses on developing novel engineered multivalent and multispecific therapeutics.

Jackie Oberst, Ph.D.

Washington, DC

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here